PlainPharmaWatch

CMS Open Payments · Tool

Teva Pharmaceuticals USA, Inc. vs Advanced Accelerator Applications

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Advanced Accelerator Applications has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 10,000, versus 40 for the other company. Its single largest recorded recipient represents 1.0% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Teva Pharmaceuticals USA, Inc.
HHI 40 · top recipient 0.0%
Ranked #1,783 of 1,838 companies by HHI
Advanced Accelerator Applications
HHI 10,000 · top recipient 1.0%
Ranked #130 of 1,838 companies by HHI

Payment Overview

Total Payments
$67.4M
% of Industry
0.5%
Transactions
148,378
Avg per Transaction
$454.55
Recipients
141,158
Avg per Recipient
$477.80
Payment Types
5
Top Payment Type
Compensation for Services Other Than Consulting
Total Payments
$63.9M
% of Industry
0.5%
Transactions
167
Avg per Transaction
$382.8K
Recipients
167
Avg per Recipient
$382.8K
Payment Types
1
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Teva Pharmaceuticals USA, Inc. vs Advanced Accelerator Applications - total reported payments in CMS Open Payments PY2024

Teva Pharmaceuticals USA, I…$67.4MAdvanced Accelerator Applic…$63.9M

Payment Types Breakdown

Teva Pharmaceuticals USA, Inc.

Compensation for Services Other Than Consulting $8.4M

12.4%

Food and Beverage $3.2M

4.8%

Travel and Lodging $1.1M

1.7%

Consulting Fee $906.0K

1.3%

Education $236.9K

0.4%

Advanced Accelerator Applications

Compensation for Services Other Than Consulting $63.9M

100.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Teva Pharmaceuticals USA, Inc.

  1. 1

    LESLIE CITROME

    $208,922.63 · 186 txns

  2. 2

    AMBER RENEE HOBERG

    $208,191.77 · 326 txns

  3. 3

    GUSTAVO ALVA

    $182,808.65 · 173 txns

  4. 4

    RAKESH JAIN

    $174,580.46 · 169 txns

  5. 5

    AMITA PATEL

    $165,823.75 · 170 txns

Advanced Accelerator Applications

  1. 1

    Univ Of Missouri Health Care

    $63,931,988.05 · 167 txns

Summary Comparison

Metric Teva Pharmaceuticals USA, Inc. Advanced Accelerator Applications
Total Payments $67.4M $63.9M
% of Industry Total 0.5% 0.5%
Transaction Count 148,378 167
Avg per Transaction $454.55 $382.8K
Recipient Count 141,158 167
Avg per Recipient $477.80 $382.8K
Payment Type Count 5 1
Top Payment Type Compensation for Services Other Than Consulting Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.